coagulation problems, Bleeding events, thromboembolic events D68.30 D68.31 D68.32 D68.38 D68.4 D68.8 I26.0 I26.9 I74.0 I74.1 I74.2 I74.3 I74.4 I74.5 I74.8 I74.9
Conditions
Interventions
Group 1: The following parameters will be included in the individualized pharmacotherapeutical risk information:
- genetical analysis (CYP2C9, CYP2C19, VCORC1)
- drug- drug interaction test
- liver v
Sponsors
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: multimorbidity, therapy with oral anticoagulation, minimum of one additional medication over a longer period of time, can give written consent to take part in the study
Exclusion criteria
Exclusion criteria: is not able to give consent ot take part in that study, is not able to understand and/or fill in the questionaire SF-36 and other forms
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bleeding occurence or occurence of a thromboembolic event during the observation period of 9 month | — |
Secondary
| Measure | Time frame |
|---|---|
| morbidity: serious adverse drug reaction during the observation period of 9 month. Number of hospitailzation due to serious adverse drug reaction. Number of specialist's referral due do problems with the medication. Number of change in medication during the observation period of 9 month. mortality: number of death during the observation period of 9 month. Effectiveness: qualtiy of life (SF-36; 3,6, and 9 month after start of the study). Cost of medication and of potantil additional doctor’s visit. cost-benefit analysis (that takes mobidity and mortality into account) | — |
Countries
Germany
Contacts
Public ContactKathrin Kastenmüller
Universitätsklinikum Bonn, Institut für Hausarztmedizin
Outcome results
None listed